Linked Life Data

20423740

Source:http://linkedlifedata.com/resource/pubmed/id/20423740

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2011-2-21
pubmed:abstractText
The aim of the study was to evaluate the effects of 12-month treatment with sibutramine plus L-carnitine compared with sibutramine alone on body weight, glycemic control, insulin resistance, and inflammatory state in type 2 diabetes mellitus patients. Two hundred fifty-four patients with uncontrolled type 2 diabetes mellitus (glycated hemoglobin [HbA(1c)] >8.0%) in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomized to take sibutramine 10 mg plus L-carnitine 2 g or sibutramine 10 mg in monotherapy. We evaluated at baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index, HbA(1c), fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, homeostasis model assessment of insulin resistance index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, leptin, tumor necrosis factor-?, adiponectin, vaspin, and high-sensitivity C-reactive protein. Sibutramine plus L-carnitine gave a faster improvement of fasting plasma glucose, postprandial plasma glucose, lipid profile, leptin, tumor necrosis factor-?, and high-sensitivity C-reactive protein compared with sibutramine alone. Furthermore, there was a better improvement of body weight, HbA(1c), fasting plasma insulin, homeostasis model assessment of insulin resistance index, vaspin, and adiponectin with sibutramine plus L-carnitine compared with sibutramine alone. Sibutramine plus L-carnitine gave a better and faster improvement of all the analyzed parameters compared with sibutramine alone without giving any severe adverse effect.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1532-8600
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
421-9
pubmed:meshHeading
pubmed-meshheading:20423740-Aged, pubmed-meshheading:20423740-Appetite Depressants, pubmed-meshheading:20423740-Blood Glucose, pubmed-meshheading:20423740-Body Weight, pubmed-meshheading:20423740-C-Reactive Protein, pubmed-meshheading:20423740-Carnitine, pubmed-meshheading:20423740-Cholesterol, pubmed-meshheading:20423740-Cyclobutanes, pubmed-meshheading:20423740-Diabetes Mellitus, Type 2, pubmed-meshheading:20423740-Double-Blind Method, pubmed-meshheading:20423740-Drug Therapy, Combination, pubmed-meshheading:20423740-Female, pubmed-meshheading:20423740-Hemoglobin A, Glycosylated, pubmed-meshheading:20423740-Humans, pubmed-meshheading:20423740-Insulin Resistance, pubmed-meshheading:20423740-Leptin, pubmed-meshheading:20423740-Longitudinal Studies, pubmed-meshheading:20423740-Male, pubmed-meshheading:20423740-Middle Aged, pubmed-meshheading:20423740-Tumor Necrosis Factor-alpha, pubmed-meshheading:20423740-Vitamin B Complex
pubmed:year
2011
pubmed:articleTitle
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.
pubmed:affiliation
Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy. giuseppe.derosa@unipv.it
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study